Once the truth was revealed, sales of Celebrex fell dramatically and Bextra
was removed from the market.
, which Pfizer voluntarily withdrew in 2005.
The FDA's decision is stunning because it went against the vote of the drug safety advisory committee, which decided in February to allow the continued marketing of COX-2 inhibitors, including Celebrex (celecoxib) and Bextra
Even if Bextra
has only half the risk associated with it as Vioxx, Kaiser Permanente clinical experts agree that the risk is too great, given the modest benefit provided by the drug," the company said.
Emerson Poynter's lawsuit is the third Pfizer faces after disclosing that Celebrex and Bextra
might increase the chances of heart problems in users.
Pfizer stood firm by its product, saying three studies involving 6,000 people found no link between the drug and an increased risk of heart disease--such a link was found for another Pfizer drug, Bextra
, in patients after bypass surgery.
Litigators will be able to track litigation involving Vioxx, Celebrex, Enbrel, Arava, Bextra
, Kineret, naproxen, Remicade, Ridaura, and other related drugs from initial complaint to final appeal.
The report will cover cases involving such arthritis drugs as Vioxx, Enbrel, Celebrex, Arava, Bextra
, Kineret, naproxen and Remicade, as well as other related drugs currently under scientific and legal scrutiny.
The labeling changes for Bextra
include a warning regarding the risk of serious skin reactions, including Stevens-Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, and erythema multi-forme.
The amended complaint will allege that during the Class Period, defendants misled investors by failing to disclose that they were engaged in an ongoing course of conduct designed to illegally promote the sale of Pfizer drugs, including Bextra
, Geodon, Zyvox and Lyrica.
3 billion settlement in 2009 over the marketing of its Bextra
painkiller and other drugs.
The pain medications Vioxx and Bextra
, and the anti-diabetic medication Avandia, cause fluid retention.